Citadel Advisors LLC lifted its stake in shares of Phio Pharmaceuticals Corp (NASDAQ:PHIO) by 148.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,621 shares of the company’s stock after purchasing an additional 51,216 shares during the quarter. Citadel Advisors LLC’s holdings in Phio Pharmaceuticals were worth $33,000 at the end of the most recent reporting period.
Separately, SG Americas Securities LLC boosted its position in shares of Phio Pharmaceuticals by 163.8% during the 2nd quarter. SG Americas Securities LLC now owns 603,528 shares of the company’s stock worth $229,000 after purchasing an additional 374,703 shares in the last quarter. Institutional investors and hedge funds own 5.27% of the company’s stock.
Separately, ValuEngine raised shares of Phio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd.
Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.08). On average, analysts anticipate that Phio Pharmaceuticals Corp will post -0.36 earnings per share for the current fiscal year.
Phio Pharmaceuticals Profile
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Recommended Story: Liquidity
Want to see what other hedge funds are holding PHIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phio Pharmaceuticals Corp (NASDAQ:PHIO).
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.